PREVALENCE OF MENSTRUAL MIGRAINE AND THE EFFICACY OF SUMATRIPTAN ADMINISTRATION
Prevalensi Migrain Menstrual dan Efikasi dari Pemberian Sumatriptan
Downloads
Background: Menstrual migraine is a primary headache that often attacks women of reproductive age. This type of migraine has high severity and is resistant to treatment. Therefore, an effective treatment is needed to treat this menstrual migraine. Sumatriptan has been shown to have a better effect as an acute treatment for menstrual migraine patients. Purpose: This study aims to determine the prevalence and effectiveness of sumatriptan as a therapy for menstrual migraine. Methods: This research is based on a literature review following predetermined inclusion criteria. First, a literature search was carried out adhering to the PRISMA flow in 4 databases: Pubmed, Science Direct, ProQuest, and ClinicalTrial.co. Results: Based on keywords, 267 studies were found in the literature search. However, only three studies covering 845 participants met the predetermined inclusion criteria. The average age of menstrual migraine patients in the three studies was 37 years. These three studies of sumatriptan revealed a significant effect in providing a pain-free response in menstrual migraine patients. These three studies also showed that sumatriptan 100 mg has a higher level of effectiveness in providing a pain-free response in menstrual migraine sufferers and was preferably given during mild attacks. Conclusion: These three studies indicate that typically, women who suffer from menstrual migraines are of reproductive age. Additionally, this study shows that using sumatriptan as an acute therapy significantly helps provide a pain-free response in menstrual migraine patients.
Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2022;12(February):1–15.
Chalmer MA, Kogelman LJA, Ullum H, Sí¸rensen E, Didriksen M, Mikkelsen S, et al. Population-based characterization of menstrual migraine and proposed diagnostic criteria. JAMA Netw open. 2023;6(5):e2313235.
Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B, et al. Male and female sex hormones in primary headaches. J Headache Pain. 2018;19(1):1–12.
Wibisono Y. The relationship between headaches in women and changes in hormone levels. Dep Neurol Fak Kedokt Univ Padjadjaran. 2019;46(1):47–50.
Chaudhary A. Migraine associated with menstruation an overlooked trigger. J Nepal Med Assoc. 2021;59(238):611–3.
Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):1–17.
Andani RW. Relationship between degree of stress and physical activity of female students with premenstrual syndrome. J Berk Epidemiol. 2020 May 31;8(2):125–33. Available from: https://e-journal.unair.ac.id/JBE/article/view/15515
Barra M, Dahl FA, MacGregor EA, Vetvik KG. Identifying menstrual migraine- improving the diagnostic criteria using a statistical method. J Headache Pain. 2019;20(1):1–12.
Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing greater recognition. Lancet Neurol. 2021;20(4):304–15.
Barus J, Sudharta H, Adriani D. Study of the mechanisms and therapeutic approaches of migraine in women and pregnancy: a literature review. Cureus. 2023;2(chromosome 19):1–9.
Pavlovic JM, Paemeleire K, Göbel H, Bonner J, Rapoport A, Kagan R, et al. Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain. 2020;21(1):1–9.
Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of estrogens in menstrual migraine. Cells. 2022;11(8):18–25.
Bellei E, Rustichelli C, Bergamini S, Monari E, Baraldi C, Lo Castro F, et al. Proteomic serum profile in menstrual-related and post menopause migraine. J Pharm Biomed Anal. 2020;184:113165.
Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019;99(1):17–24.
Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol. 2003;102(4):835–42.
Landy S, Savani N, Shackelford S, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract. 2004;58(10):913–9.
Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain. 2005 Apr;6(2):81–7.
Ohk B, Seong S, Lee J, Gwon M, Kang W, Lee H, et al. Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling. Biopharm Drug Dispos. 2022;43(1):23–32.
Pavlović JM. The impact of midlife on migraine in women: summary of current views. Women's Midlife Heal. 2020;6(1):1–7.
Faubion SS, Batur P, Calhoun AH. Migraine throughout the female reproductive life cycle. Mayo Clin Proc. 2018;93(5):639–45.
Ansari T, Lagman-Bartolome AM, Monsour D, Lay C. Management of menstrual migraine. Curr Neurol Neurosci Rep. 2020;20(10):1–6.
Fernández-Martínez E, Onieva-Zafra MD(. MD, Abreu-Sánchez A, González-Sanz JD, Iglesias-López MT, Fernández-Muñoz JJ, et al. Menstrual migraine among spanish university students. J Pediatr Nurs. 2021;56(xxxx):e1–6.
Wang M, Zhu G, Song Z, Kong F. Clinical differences between menstrual migraine and nonmenstrual migraine: a systematic review and meta-analysis of observational studies. J Neurol. 2023;270(3):1249–65.
Martin VT. Menstrual Migraine: New Approaches to Diagnosis and Treatment. 2018;7–8.
Roeder HJ, Leira EC. Effects of the Menstrual cycle on neurological disorders. Curr Neurol Neurosci Rep. 2021;21(7).
Nandar Kurniawan S, Kusuma Wardhani D. Classical migraine. JPHV (Journal Pain, Vertigo Headache). 2022;3(2):35–40.
Rad RF, Sadrabad AZ, Jafari M, Ghilian M. Efficacy of sumatriptan/placebo versus sumatriptan/ propofol combination in acute migraine; a randomized clinical trial. Arch Acad Emerg Med. 2022;10(1):1–7.
Huang PC, Yang FC, Chang CM, Yang CP. Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment. Prog Brain Res. 2020;255:99–121.
Tfelt-Hansen P, Diener HC. Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks. Cephalalgia. 2020;40(12):1331–5.
Okonkwo K, Ojha U. Vasospasm induced myocardial ischaemia secondary to sumatriptan use. BMJ Case Rep. 2020;13(8):1–4.
- Every manuscript submitted to must observe the policy and terms set by the Jurnal Berkala Epidemiologi
- Publication rights to manuscript content published by the Jurnal Berkala Epidemiologi is owned by the journal with the consent and approval of the author(s) concerned. (download copyright agreement)
- Complete texts of electronically published manuscripts can be accessed free of charge if used for educational and research purposes according to copyright regulations.
JBE by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
